Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH ®) in 14 patients with severe haemophilia A

Haemophilia

Volumn 17, Issue 5, 2011, Pages

  Bidlingmaier, C ^a   Kurnik, K ^a   Escuriola Ettingshausen, C ^b   Jager, R ^c   Klamroth, R ^d   Male, C ^e   Marosi, A ^f   Nemes, L ^g   Von Stackelberg, A ^h   Kreuz, W ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c West Regional Haemophilia Centre   (Hungary)

^d VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f HEIM PÁL CHILDREN S HOSPITAL   (Hungary)

^g State Health Center   (Hungary)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

CATHETER COMPLICATION; CATHETER INFECTION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE DELETION; GENE MUTATION; HEMOPHILIA A; HUMAN; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFECTION COMPLICATION; INTRON; LETTER; LOW DRUG DOSE; OUTCOME ASSESSMENT; PERTUSSIS; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RASH; SKIN NECROSIS; THROMBOSIS; TONSILLITIS; URTICARIA;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; MALE; MIDDLE AGED; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 80052028758     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02577.x     Document Type: Letter

References (10)

1. Kaveri S, Mannucci PM, Kurth MH et al. von Willebrand factor: what is its role in the immune response in haemophilia? Haemophilia 2011; 17: e235-8.
2. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
3. DiMichele DM, Goldberg I, Foulkes M. International prospective randomized immune tolerance (ITI) study: preliminiary results of therapeutic efficacy and safety. Haemophilia 2010; 16(Suppl.): 4:29 (07S03).
4. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
5. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
6. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members. Vox Sang 1999; 77(Suppl. 1): 31-2.
7. Coppola A, Margaglione M, Santagostino E et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
8. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
9. Kreuz W, Ettingshausen CE, Auerswald G et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
10. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007; 13(Suppl. 5): 73-7.